-
1.
公开(公告)号:US20060122229A1
公开(公告)日:2006-06-08
申请号:US10538318
申请日:2003-12-18
Applicant: Anna Berggren , Stig Bostrom , Stig Elebring , Linda Fallefors , Johan Wilstermann , Peter Greasley
Inventor: Anna Berggren , Stig Bostrom , Stig Elebring , Linda Fallefors , Johan Wilstermann , Peter Greasley
IPC: A61K31/454 , A61K31/427 , A61K31/426 , C07D417/02
CPC classification number: C07D417/04 , C07D277/56 , C07D417/12
Abstract: The present invention relates to compounds of formula (I): in which R1 and R2 independently represent phenyl, thienyl or pyridyl and R3 represents a group —X—Y—NR4R5 in which X is CO or SO2; Y is absent or represents NH and the other substituente are as defined in the description and their use in the treatment of obesity, psychiatric and neurological disorders and to pharmaceutical compositions containing them.
Abstract translation: 本发明涉及式(I)化合物:其中R 1和R 2独立地代表苯基,噻吩基或吡啶基,R 3, 表示其中X为CO或SO 2的基团-XY-NR 4 R 5, Y不存在或表示NH,另一个取代基如描述中所定义,以及它们在治疗肥胖,精神病和神经障碍中的用途以及含有它们的药物组合物。
-
2.
公开(公告)号:US20060122230A1
公开(公告)日:2006-06-08
申请号:US10540276
申请日:2003-12-18
Applicant: Anna Berggren , Stig Bosfrom , Leifeng Cheng , Stig Elebring , Peter Greasley , Mats Nagard , Johan Wilstermann , Emma Terricabras
Inventor: Anna Berggren , Stig Bosfrom , Leifeng Cheng , Stig Elebring , Peter Greasley , Mats Nagard , Johan Wilstermann , Emma Terricabras
IPC: A61K31/454 , A61K31/4015 , A61K31/401
CPC classification number: C07D401/04 , A61K31/402 , A61K31/4025 , A61K31/454 , C07D207/34 , C07D401/06
Abstract: The present invention relates to a compound of formula (I) in which R1 and R2 independently represent phenyl, thienyl or pyridyl each of which is optionally substituted by one, two or three groups represented by Z; and R3 is H, a C1-3alkyl group, a C1-3alkoxymethyl group, trifluoromethyl, a hydroxyC1-3alkyl group, an aminoC1-3alkyl group, C1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C1-3alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula —CONHNRaRb wherein Ra and Rb are as defined for R4 and R5 respectively; X is CO or SO2; Y is absent or represents NH optionally substituted by a C1-3alkyl group; R4 and R5 independently represent: a C1-6alkyl group; an (amino)C1-4alkyl-group in which the amino is optionally substituted by one or more C1-3alkyl groups; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)s; naphthyl; anthracenyl; a saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen wherein the heterocyclic group is optionally substituted; 1-adamantylmethyl; a group —(CH2)t Het where Het represents an aromatic heterocycle optionally substituted; or R4 represents H and R5 is as defined above; or R4 and R5 together with the nitrogen atom to which they are attached represent a saturated 5 to 8 membered heterocyclic group; R6 is H, a C1-3alkyl group, a C1-3alkoxymethyl group, trifluoromethyl, a hydroxyC1-3alkyl group, C1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C1-3alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula —CONHNRaRb; with provisos; to processes for preparing such compounds, to their use in the treatment of obesity, psychiatric and neurological disorders particularly obesity, to methods for their therapeutic use and to pharmaceutical compositions containing them.
-
公开(公告)号:US20050032808A1
公开(公告)日:2005-02-10
申请号:US10499054
申请日:2002-12-18
Applicant: Anna Berggren , Stig Jonas Bostrom , Stig Elebring , Peter Greasley , Emma Terricabras , Johan Wilstermann
Inventor: Anna Berggren , Stig Jonas Bostrom , Stig Elebring , Peter Greasley , Emma Terricabras , Johan Wilstermann
IPC: C07D241/24 , A61K20060101 , A61K31/495 , A61K31/4965 , A61K31/497 , A61P20060101 , A61P3/04 , A61P7/00 , A61P9/10 , A61P15/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P37/00 , A61P43/00 , C07D20060101
CPC classification number: C07D241/24
Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R1 and R2 independently represent: a C1-6alkyl group; an optionally substituted (amino)C1-4alkyl-group; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)s in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group —(CH2)t Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or R1 represents H and R2 is as defined above; or R1 and R2 together with the nitrogen atom to which they are attached represent a saturated optionally substituted 5 to 8 membered heterocyclic group as defined above; X is CO or SO2; Y is absent or represents NH optionally substitututed by a C1-3alkyl group; R3 and R4 independently represent phenyl, thienyl or pyridyl substituted by Z; Z represents a C1-3alkyl group, a C1-3alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, trifluoromethylsulphonyl, nitro, amino, mono or di C1-3alkylamino, mono or di C1-3alkylamido, C1-3alkylsulphonyl, C1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C1-3alkyl carbamoyl, sulphamoyl and acetyl; and R5 is H, a C1-3alkyl group, a C1-3alkoxymethyl group, trifluoromethyl, a hydroxyC1-3alkyl group, C1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C1-3alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula —CONHNRaRb; with the provisos; and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
-
-